Story perspectives

EnGene's Bladder Cancer Trial Shows Promising 62% Response Rate

11/12/2025

27 2

Summary

Story summary

EnGene Holdings Inc. reported a 62% complete response rate in its Phase 2 LEGEND trial for high-risk, BCG-unresponsive non-muscle invasive bladder cancer, involving 125 patients.
The trial demonstrated a 56% response rate at three months and a 63% rate at any time.
Following these results, EnGene's stock increased over 50%, indicating strong market confidence.
The company plans to file a Biologics License Application in the second half of 2026 for detalimogene as a first-line therapy.
Safety data showed manageable treatment-related adverse events, primarily mild.

1 of 1

Story summary

EnGene Holdings Inc. reported a 62% complete response rate in its Phase 2 LEGEND trial for high-risk, BCG-unresponsive non-muscle invasive bladder cancer, involving 125 patients.
The trial demonstrated a 56% response rate at three months and a 63% rate at any time.
Following these results, EnGene's stock increased over 50%, indicating strong market confidence.
The company plans to file a Biologics License Application in the second half of 2026 for detalimogene as a first-line therapy.
Safety data showed manageable treatment-related adverse events, primarily mild.